OncoMatch/Clinical Trials/NCT07042802
A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer
Is NCT07042802 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies multiple treatments including LBL-024 for and Paclitaxel for ovarian cancer.
Treatment: LBL-024 for · Paclitaxel — This trial is an open-label, multicenter phase Ib/II clinical study of LBL-024 combination therapy in patients with platinum-resistant ovarian cancer (OC),To evaluate the efficacy and safety of LBL-024 combination therapy in the treatment of advanced recurrent platinum-resistant ovarian cancer (OC) patients.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: platinum-based chemotherapy
Platinum-resistant Ovarian Cancer
Cannot have received: investigational agent
has received or is receiving other investigational agents within 4 weeks prior to the first dose of study drug
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify